Sandostatin (Octreotide LAR) may lead to clinical improvement through receptor occupation optimisation. A prospective interventional trial of patients with neuro-endocrine tumors with carcinoid syndrome receiving octreotide LAR.
Phase of Trial: Phase IV
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Octreotide (Primary)
- Indications Carcinoid tumour; Diarrhoea; Neuroendocrine tumours
- Focus Therapeutic Use
- 19 Aug 2016 New trial record